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ABSTRACT
We have compared the influence of insulin-like growth factor 1
(IGF-1) on pituitary gene expression in the rat cell lines GH4C1 and
GH3. Incubation with IGF-1 increased PRL messenger RNA (mRNA)
levels in GH4C1 cells by 4- to 5-fold but decreased the levels of PRL
transcripts in GH3 cells. In addition, the levels of GH-mRNA that
were not affected by IGF-1 in GH4C1 cells were significantly inhibited
by the growth factor in GH3 cells. IGF-1 also decreased PRL and
GH-mRNA response to T3, retinoic acid, and Fk in GH3 cells. Stability
of PRL or GH transcripts was not altered by IGF-1 in GH3 cells,
suggesting that the inhibitory effect is exerted at a transcriptional
level. The pituitary-specific transcription factor GHF-1/Pit-1 acti-
vates both the GH and PRL promoters. As analyzed by Western blot,
IGF-1 did not alter GHF-1/Pit-1 protein levels in GH4C1 cells but
reduced the levels of the transcription factor in GH3 cells. This de-
crease is secondary to a reduction of GHF-1/Pit-1 transcripts in IGF-
1-treated GH3 cells. Thus, a different effect of IGF-1 on the expression
of GHF-1/Pit-1 in GH3 and GH4C1 cells is likely involved in the
different regulation of GH and PRL gene in both cell types. IGF-1
increases the activity of the PRL promoter in transient transfection
assays in GH4C1 cells by a Ras-dependent mechanism. Expression of
oncogenic RasVal12 mimics the effect of IGF-1, and the dominant
negative RasAsn17 blocks IGF-1-mediated stimulation of the PRL pro-
moter in GH4C1 cells. Although IGF-1 did not stimulate the PRL
promoter in GH3 cells, RasVal12 strongly activated the promoter in
these cells. Hence, the machinery to activate Ras-dependent signaling
is intact in GH3 cells. Moreover, IGF-1 stimulates the mitogen-acti-
vated protein kinase in GH3 cells, showing that the components
linking the IGF-1 receptor to Ras are also active. These results sug-
gest that, in addition to the Ras/mitogen-activated protein kinase
pathway, IGF-1 could activate a different pathway and that the com-
bination of both is required to elicit PRL gene expression by the
growth factor. This second pathway may be defective in GH3 cells that
respond to Ras but not to IGF-1. (Endocrinology 138: 5442–5451,
1997)
THE RAT tumor cell lines have been widely used forstudies of regulation of expression of pituitary cells,
because they retain the capacity to synthesize and secrete GH
and PRL in a hormone-regulated manner. Expression of both
genes is dependent on the presence of the pituitary-specific
transcription factor GHF-1/Pit-1, which is transcribed in a
highly restricted manner in cells of the anterior pituitary (1,
2). Multiple hormones, growth factors, and oncogenes act in
conjunction with GHF-1/Pit-1 to regulate pituitary-specific
expression of the PRL and GH genes.
The actions of insulin-like growth factor 1 (IGF-1) are
mediated by ligand activation of a tyrosine kinase receptor.
IGF-1 receptors are expressed in a variety of cell types, in-
cluding anterior pituitary cells and pituitary cell lines (3).
Binding of IGF-1 is followed by a rapid activation of the
intrinsic tyrosine activity of the receptor, phosphorylation of
several protein substrates, and activation (among others) of
phosphatidylinositol-3 kinase and Ras. Activation of Ras ini-
tiates an intracellular signaling cascade of serine/threonine
kinases. Raf, MEK, and mitogen-activated protein (MAP)
kinases are downstream components of this pathway, which
has been shown to result in phosphorylation of numerous
substrates, including nuclear transcription factors (4, 5). A
rapid and strong activation of the MAP kinases (MAP-K),
ERK-1 and ERK-2, by IGF-1 recently has been observed in the
rat pituitary GC cell line (6).
It has been described that IGF-1 suppresses basal GH-
messenger RNA (GH-mRNA) levels, as well as GH-releasing
hormone (GH-RH)- and T3-induced GH-mRNA stimulation
(7) in primary cultures of rat pituitary cells. This suppression
has been shown to be secondary to a direct inhibition of the
GH gene transcription rate (8, 9), although the relationship,
if any, between activation of the Ras/MAP-K pathway and
IGF-1-mediated suppression of GH gene transcription re-
mains to be established. The inhibition of GH gene tran-
scription by IGF-1 in primary pituitary cells is selective,
because expression of the PRL gene was unaffected by IGF-1
in these cells (7). In contrast with the results obtained in
primary cultures, we very recently have observed that GH-
mRNA levels are not suppressed by IGF-1 in GH4C1 cells, a
rat pituitary tumor cell line. Furthermore, the growth factor
significantly induces PRL gene expression in GH4C1 cells
through sequences located in the proximal promoter
(Castillo, A. I., R. Tolon, and A. Aranda, manuscript sub-
mitted). It has been shown that expression of a constitutively
active Ras oncogene produces a strong activation of the PRL
promoter and that Raf, MAP-K, and Ets-1 are crucial com-
ponents of the downstream transmission of the Ras signal in
the regulation of PRL promoter activity (11–13). Our results
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have demonstrated that activation of the PRL promoter by
IGF-1 in GH4C1 cells requires activation of the Ras/MAP-K
pathway, because dominant negative mutants of these pro-
teins block stimulation of PRL gene expression by IGF-1. Our
results also suggest that IGF-1 could stimulate additional,
independent pathway(s), which cooperate with the Ras/
MAP-K to elicit PRL gene expression.
In this study, we have compared the regulation of PRL,
GH, and GHF-1/Pit-1 gene expression in pituitary GH4C1
and GH3 cells. Both cell lines are closely related and have
retained the ability of normal somatolactototropes to pro-
duce GH and PRL. The GH3 cells were cloned from pituitary
tumor cells transferred twice between animal and tissue cul-
ture, and the GH4C1 cells are a cloned variant of the GH3
cells (14). Our results show a strikingly different regulation
of these genes by IGF-1. In GH4C1 cells, the growth factor
induces PRL gene expression without significantly affecting
the GH gene. In contrast, IGF-1 strongly inhibits PRL and GH
gene expression in GH3 cells. This occurs despite the fact that
oncogenic Ras activates the PRL promoter in GH3 cells and
that IGF-1 activates the MAP-Ks in a manner indistinguish-
able from that found in GH4C1 cells. A differential regulation
of GHF-1/Pit-1 might contribute to the different regulation
of GH and PRL gene expression in both cell lines. Expression
of the GHF-1/Pit-1 gene is suppressed by IGF-1 in GH3 cells,
where the growth factor inhibits pituitary-specific gene ex-
pression, but is not reduced in GH4C1 cells, where it activates
the PRL gene.
Materials and Methods
RNA extraction and hybridization
GH4C1 cells were grown in DMEM containing 10% FCS, and GH3
cells were cultured in RPMI medium containing 15% donor horse serum
and 2.5% FCS (GIBCO BRL, Grand Island, NY). The cells were incubated
for 24 h in a medium containing 10% AG1-X8 resin-charcoal stripped
newborn calf serum and then treated with IGF-1, insulin, triiodothyro-
nine (T3), forskolin (Fk), or retinoic acid (RA) in serum-free medium, as
indicated in the figures. Total RNA was extracted from the cell cultures
with guanidine thiocyanate (15). The RNA was run in 1% formaldehyde-
agarose gels and transferred to nylon-nitrocellulose membranes (Nyt-
ran, Schleicher & Schuell, Kenne, NH) for Northern blot analysis. The
RNA was stained with 0.02% methylene blue. The blots were hybridized
with labeled cDNA probes for rat PRL (16), GH (17), or GHF-1 (18).
Hybridizations were carried out at 421⁄4 C with 50% formamide and the
more stringent wash was at 421⁄4 C with 13SSC-0.1% SDS. Quantification
of mRNA levels was carried out by densitometric scan of the autora-
diograms. The values obtained were always corrected by the amount of
RNA applied in each lane, which was determined by densitometry of the
stained membranes.
Plasmids
GH-chloramphenicol acetyltransferase (CAT) constructs containing
2530 bp of the rat GH promoter have been described previously (19).
The plasmid 2400rGHF-1-CAT (20) contains sequences of the rat GHF-1
promoter ligated to CAT. The plasmids 23000Prl-CAT and 2176Prl-
CAT contain 59-flanking sequences of the rat PRL promoter (21). Con-
stitutive expression vectors for oncogenic Ha-ras Val12 (22), the dominant
inhibitory Ha-ras Asn17 mutant (23), GHF-1 (24), and the IGF-1 receptor
(pBPV-IGF1-R) (25) also were used in transient transfection assays.
Cell culture and transfections
GH4C1 or GH3 cells were transfected by electroporation, as previ-
ously described (19, 26, 27). Ten micrograms of the reporter plasmids
were mixed with 20–30 million cells and exposed to a high-voltage pulse
(200–250 V, 960 mF) by using a Bio-Rad (Bio-Rad Laboratories, Rich-
mond, CA) electroporator with a capacitor extender. The cells from each
electroporation were split into different culture plates and incubated
overnight in DMEM containing 10% AG138 resin-charcoal stripped
newborn calf serum. This hormone-depleted medium was replaced by
serum-free medium, and the treatments were administered. In some
assays, in which the cells were cotransfected with the PRL reporter
construct and expression vectors, the amount of DNA was kept constant
by addition of the same amount of an empty noncoding vector (RSV-0).
Each transfection also received 2.5 mg of a luciferase vector to monitor
transfection efficiency. Each treatment with the ligands was performed,
at least, in duplicate cultures that normally exhibited less than 10%
variation in CAT activity. CAT activity was determined by incubation
of the cell extracts with [14C]chloramphenicol. The unreacted and acety-
lated [14C]chloramphenicol were separated by TLC, identified by au-
toradiography, and quantified. The data are expressed as the percentage
of acetylated forms after each treatment. Each experiment was repeated
at least two or three times with similar relative differences in regulated
expression.
Western blot analysis
The levels of GHF-1/Pit-1 were determined by Western blot analysis.
GH4C1 or GH3 cell extracts (10 mg) were run in a 12% polyacrylamide
gel. The proteins were transferred to a nitrocellulose membrane and
incubated with a 1:1000 dilution of a polyclonal antibody that recognizes
the transcription factor, and GHF-1/Pit-1 was identified by chemilu-
minescence (24).
Determination of MAP-K activity
GH4C1 and GH3 cells were plated in 60-mm diameter dishes in
growth medium. After 24 h, cells were switched to a resin-charcoal
depleted medium, and after an additional 12 h period, were serum
starved for 18 h and exposed to 13 nm IGF-1 or 100 nm phorbol 12-
myristate 13-acetate (TPA) for different time periods. Cells were then
lysed in 300 ml of cold lysis buffer (10 mm EGTA, 40 mm b-glycero-
phosphate, 1% NP-40, 2.5 mm MgCl2, 2 mm orthovanadate, 1 mm Di-
thiothreitol, 20 mm HEPES, pH 7, 5) containing protease inhibitors
(leupeptin, aprotinin, benzamidine, and phenylmethylsulfonyl fluo-
ride). Cell extracts (100 mg) were incubated with 5 ml ERK-2 (C-14) rat
polyclonal antibody (Santa Cruz Biotechnology, Gebuhrenfrei, Ger-
many) at 4 C for 1 h. Protein A-Sepharose was added and the samples
incubated for an additional hour and centrifuged. The pellets were
washed three times with PBS, 1% NP-40, and 2 mm orthovanadate; and
once with 0.1 m Tris-ClH (pH 7.5), 0.5 m LiCl, and kinase buffer (2 mm
Dithiothreitol, 20 mm glycerophosphate, 20 mm PnPP, 20 mm MgCl2, 0.1
mm orthovanadate, and 20 mm HEPES, pH 7.6). The immunoprecipi-
tates were then incubated in 30 ml of kinase buffer containing 20 mm ATP,
2 mCi of g-32P-ATP, and 1 mg myelin basic protein (MBP) as a substrate.
After incubation for 20 min at 30 C, the samples were subjected to
SDS-PAGE in 15% acrylamide gels, dried, and autoradiographed. MBP
band density on the autoradiographs was quantitated by densitometry.
Results
Influence of IGF-1 on PRL- and GH-mRNA levels in
GH4C1 and GH3 cells
Figure 1 compares the effect of a 48-h incubation with 13
nm IGF-1 on PRL and GH-mRNA levels in GH4C1 and GH3
cells. IGF-1 significantly increased (4- to 5-fold) PRL tran-
scripts in GH4C1 cells. In contrast with these results, IGF-1
caused a strong decrease of PRL mRNA levels in GH3 cells.
A reduction of GH-mRNA levels also was observed in IGF-
1-treated GH3 cells, whereas this factor did not significantly
alter GH transcripts in GH4C1 cells. Quantification of North-
ern blots from five different experiments showed that IGF-1
reduced by 40–75% Prl- and GH-mRNA levels in GH3 cells.
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In GH41 cells, GH-mRNA levels only varied between 0 and
15% after treatment with IGF-1.
The effect of IGF-1 in combination with T3 on PRL and GH
gene expression also was analyzed in both cell lines. Treat-
ment with 5 nm T3 stimulated PRL mRNA levels in both
GH4C1 and GH3 cells. In GH3 cells, this response was
strongly suppressed in the presence of IGF-1, whereas IGF-1
did not inhibit this response in GH4C1 cells. T3 consistently
induced GH gene expression in both cell lines, and IGF-1 was
able to partially inhibit the stimulatory effect of T3 on GH
gene expression in GH3 cells. In the experiment illustrated in
the figure, induction by T3 decreased from 6-fold in the
absence of IGF-1, to 4-fold in its presence. This inhibition was
less marked in GH4C1 cells and was not consistently ob-
served in independent experiments.
We also examined the response to IGF-1 in RA-treated
cells. Figure 2 shows GH and PRL-mRNA levels in GH3 and
GH4C1, incubated for 48 h with 1 mm RA in the presence and
absence of IGF-1. In results similar to those obtained with T3,
IGF-1 reduced the GH response to RA in GH3 cells. In ad-
dition, we observed that RA increases PRL transcripts in both
GH4C1 and GH3 cells. The induction of PRL-mRNA by RA
is less marked than that of GH-mRNA, but it was consistently
observed in different experiments. IGF-1 also decreased sig-
nificantly the PRL response to RA in GH3 cells, whereas it
acted additively with RA to increase PRL transcripts in
GH4C1 cells.
Figure 3 shows the influence of incubation with IGF-1 on
the PRL response to 10 mm Fk. Again, IGF-1 significantly
reduced the basal levels of PRL transcripts in GH3 cells.
Incubation with Fk for 48 h increased by about 2-fold PRL-
mRNA and significantly attenuated the inhibitory response
of IGF-1. In contrast, IGF-1 induced PRL-mRNA levels more
strongly than Fk in GH4C1 cells, and these levels were max-
imal with the combination of Fk and IGF-1.
Regulation of PRL promoter activity in GH4C1 and GH3
cells
The 59-flanking region of the PRL gene mediates tran-
scriptional responses to several hormones and second mes-
sengers. Experiments, in which GH4C1 and GH3 cells are
transfected with a Prl-CAT construct containing 3000 bp of
the rat PRL promoter, are shown in Fig. 4A. Incubation with
IGF-1 produced a significant increase of CAT activity in
GH4C1 cells transfected with the 23000Prl-CAT construct.
The proximal region of the PRL gene is sufficient to mediate
this response, because IGF-1 increases the activity of a PRL
promoter construct containing only 176 bp (2176Prl-CAT) to
an extent similar to that found with 23000Prl-CAT (data not
FIG. 1. IGF-1 inhibits the effect of T3
on PRL and GH transcripts in GH3
cells. The cells were incubated with 13
nM IGF-1 and/or 5 nM T3 for 48 h. North-
ern blot analyses were carried out with
20 mg of total RNA from GH3 cells (right
panels) and GH4C1 cells (left panels).
The blots were sequentially hybridized
with labeled cDNA probes for PRL (Prl)
and GH. The lower panels show the ri-
bosomal RNAs (rRNA), stained with
methylene blue.
FIG. 2. Influence of IGF-1 and RA on
PRL and GH transcripts in pituitary
GH4C1 and GH3 cells. Northern blot
analysis was carried out with RNA ex-
tracted from cells incubated for 48 h
with 13 nM IGF-1 alone or in combina-
tion with 1 mM RA, as indicated.
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shown). Incubation with Fk activated the 23000Prl-CAT con-
struct in GH4C1 cells (28, 29), and CAT activity was maximal
in cells incubated with the combination of IGF-1 and Fk.
However, Fk caused an apparent attenuation of the IGF-1
response. Fk treatment seems to decrease the IGF-1 response
from 3-fold in the absence of the cAMP stimulator, to only
2-fold in its presence.
According to the data presented in Figs. 1–3, where IGF-1
decreased PRL-mRNA levels in GH3 cells, it was expected
that IGF-1 should decrease PRL promoter activity in these
cells. However, we have not been able to find regulation of
the PRL promoter by IGF-1 in transient transfection assays.
As shown in panel A, Fk stimulated the PRL promoter, but
IGF-1 was ineffective in regulating either basal activity or the
response to the activator in GH3 cells.
The stimulatory effect of IGF-1 on the PRL promoter in
GH4C1 cells was specific for this promoter. Figure 4B shows
that the growth factor does not significantly induce GH pro-
moter activity in GH4C1 cells. This promoter was strongly
activated by T3, and IGF-1 did not alter this response. Ad-
ditionally, there was not a significant inhibition of GH pro-
moter activity by IGF-1 in this cell line (Fig. 4B), despite the
finding that basal and induced levels of GH transcripts were
significantly reduced.
It was conceivable that, if insulin receptors are expressed
at substantial levels in GH4C1 cells, the stimulation of the
PRL promoter by IGF-1 may reflect binding of IGF-1 to the
insulin receptor. However, as shown in Fig. 5, this possibility
can be dismissed. IGF-1 caused a dose-dependent stimula-
tion of the 23000Prl-CAT construct in GH4C1 cells, with a
half-maximal response found at approximately 2 nm. How-
ever, incubation with insulin, at concentrations similar to
those of IGF-1, was unable to affect the PRL promoter in these
cells. Neither IGF-1 nor insulin had a significant effect on the
activity of the PRL promoter in GH3 cells (data not shown).
One potential mechanism for the differences in the regu-
lation of PRL promoter activity between both cell lines could
be that GH3 cells may have inadequate levels of IGF-1 re-
ceptors, relative to GH4C1 cells. To test this possibility, both
cell types were cotransfected with the 23000Prl-CAT con-
struct and an expression vector for the IGF-1 receptor. Upon
overexpression of the receptor, IGF-1 strongly increased pro-
FIG. 3. Fk antagonizes the inhibitory
effect of IGF-1 in GH3 cells. GH-mRNA
and PRL-mRNA levels were deter-
mined in cells incubated for 48 h with 13
nM IGF-1 and/or 10 mM Fk.
FIG. 4. Comparison of the effect of IGF-1 on PRL and GH promoter activity in GH4C1 and GH3 cells. The cells were transiently transfected
with 10 mg of the construct 23000Prl-CAT containing the 59 flanking region of the rat prolactin promoter (panel A), or with the same amount
of the construct 2530GH-CAT, which contains the rat GH promoter (panel B). CAT activity was determined in cells treated for 48 h with medium
alone (2) or in the presence of 13 nM IGF-1 and/or 10 mM Fk. The data represent the mean 6 SD obtained from three independent transfections.
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moter activity (approximately 16-fold) in GH4C1 cells,
whereas the growth factor had little, if any, effect in GH3 cells
(Fig. 6). These data show that high levels of IGF-1 receptors
are not sufficient to activate the PRL promoter in GH3 cells
and that the amount of IGF-1 receptors is limiting in GH4C1
cells.
IGF-1 does not alter the half-life of PRL or GH mRNAs in
GH3 cells
Because IGF-1 strongly decreases GH and PRL mRNA
without significantly affecting the activity of the constructs
containing the 59-flanking region of the PRL gene, it was
possible that the main effect of IGF-1 was exerted at a post-
transcriptional level by decreasing mRNA half-life. To test
this possibility, GH and PRL-mRNA levels were determined
in control GH3 cells and in cells incubated with IGF-1, T3, or
the combination of both for 48 h and then incubated for
varying times with 5 mg/ml actinomycin D, an inhibitor of
RNA synthesis (Fig. 7). In a group of cells that did not receive
the inhibitor, PRL and GH transcripts remain stable during
30 h, the longest time period studied (data not shown). Right
panel shows that PRL-mRNA is very stable and disappeared
with a similar half-life in both untreated and IGF-1-treated
cells. The stimulatory effect of T3 did not reflect stabilization
of PRL transcripts, which have a calculated half-life of ap-
proximately 17 h, both in the presence and absence of IGF-1
(right panel). GH-mRNA also was very stable in GH3 cells,
with a similar half-life (22 h), regardless of the different
treatments (left panel). Therefore, the decrease in GH and PRL
transcripts in GH3 cells is not secondary to destabilization of
these mRNAs on incubation with IGF-1.
Effect of activated- and dominant-negative Ras mutants on
the PRL promoter
It has been demonstrated that oncogenic Ras significantly
increases PRL promoter activity in pituitary cell lines, and we
have evidence that endogenous Ras is required for induction
of the activity of the PRL promoter by IGF-1 in GH4C1 cells.
Because IGF-1 does not activate the PRL promoter in GH3
cells, there was the possibility that a component of the Ras
signaling pathway was inactive in these cells. Figure 8 com-
pares the effect of oncogenic RasVal12 on PRL promoter ac-
tivity in GH4C1 and GH3 cells treated with IGF-1 alone or
in combination with Fk. Expression of oncogenic Ras
strongly activated the PRL promoter in GH4C1 cells (panel
A). Interestingly, IGF-1 further increased promoter activity
in the presence of oncogenic Ras. Although IGF-1 was unable
to regulate PRL promoter activity in GH3 cells, expression of
oncogenic RasVal12 strongly induced the activity of the PRL
CAT plasmid in these cells (panel B), showing that the sig-
naling pathway downstream of Ras is intact in these cells. As
expected (29), Fk did not stimulate the promoter in GH4C1
or GH3 cells expressing Ras, and in agreement with the data
shown in Fig. 4A, the response to IGF-1 (expressed as fold-
induction) decreased in Fk-treated cells. The dominant neg-
ative RasAsn17 mutant blocked specifically the induction
caused by IGF-1 in GH4C1 cells, confirming that activation
of the PRL promoter by this factor requires functional en-
dogenous Ras; but this mutant did not affect the PRL pro-
moter in GH3 cells, where IGF-1 was inactive.
Stimulation of MAP-K activity by IGF-1 in GH3 and
GH4C1 cells
The lack of stimulation of the PRL gene by IGF-1 in GH3
cells could reflect uncoupling of the receptor from the Ras/
MAPK pathway. If this were the case, a downstream com-
ponent of this pathway, such as the MAP-K, should not be
activated in response to IGF-1 in these cells. Alternatively,
this response could be preserved in GH3 cells; and an ad-
ditional pathway, different from the Ras/MAPK pathway,
also required for PRL gene regulation by IGF-1, would be
lost. We have therefore examined the MAP-K response to
IGF-1 in GH3 cells. Figure 9 compares MAP-K activity ob-
tained in lysates from GH3 and GH4C1 cells incubated with
IGF-1 for increasing time periods. IGF-1 produced a rapid
and transient MAP-K activation in GH3 cells that was not
FIG. 6. Influence of overexpression of the IGF-1 receptor on the ac-
tivity of the PRL promoter. GH4C1 and GH3 cells were transfected
with 10 mg of the PRL promoter construct in the presence or absence
of 2 mg of an expression vector encoding the IGF-1 receptor (IGF-R).
The cells were treated or not with 13 nM IGF-1 for 48 h, as indicated,
and CAT activity determined. The data represent the mean 6 SD from
triplicate cultures.
FIG. 5. Insulin does not regulate PRL promoter activity in GH4C1
cells. The cells were transfected with 10 mg of the construct 23000Prl-
CAT and incubated with increasing concentrations of IGF-1 (F) or
insulin (E). CAT values were determined after 48 h of treatment in
duplicate cultures and are expressed as fold-induction over the basal
levels obtained in untreated cells.
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significantly different from that found in GH4C1 cells. In
both cell types, a maximal effect was found at 2–6 min, and
the values returned to normal after 10 min. An incubation
with 100 nm TPA for 10 min was used as a control of MAP-K
activation in these cells. At this time, TPA caused a stimu-
lation that was at least two-fold stronger that the maximal
IGF-1 induction.
Influence of IGF-1 on GHF-1/Pit-1 expression in GH4C1
and GH3 cells
The different behavior of the PRL and GH genes in GH4C1
and GH3 cells could be related to a different regulation of
GHF-1/Pit-1 gene expression by IGF-1. For instance, the
decrease in PRL and GH transcripts in IGF-1-treated GH3
cells could be secondary to a reduction in the concentration
of GHF-1/Pit-1 that activates both genes. To test this hy-
pothesis, Western blot analysis was performed with extracts
from GH4C1 and GH3 cells. Proteins obtained from control
cells and from cells treated with 13 nm IGF-1 for 48 h were
assayed using a specific anti-GHF-1/Pit-1 antibody. Figure
10 (panel A) shows that the concentration of the 33-kDa
protein doublet of GHF-1/Pit-1 protein was decreased in
GH3 cells treated with IGF-1. Quantification of this blot and
additional experiments showed that treatment with IGF-1
FIG. 7. IGF-1 does not alter the half-life of GH or PRL transcripts in GH3 cells. The cells were first incubated with 5 nM T3 and/or 13 nM IGF-1
for 48 h. The culture medium was changed (time 0) and the cells incubated with medium containing 5 mg/ml actinomycin D. At the times
indicated, RNA was extracted from duplicate cultures of control cells (E) or cells treated with IGF-1 (F), T3 (M), or IGF-1 1 T3 (f). Left panel,
Levels of GH-mRNA; right panel, levels of PRL-mRNA. The data are expressed as percentages of the levels obtained at time 0 for each treatment.
FIG. 8. Ras activates the PRL promoter in GH3 and GH4C1 cells. The cells were cotransfected with 10 mg of 3000Prl-CAT alone or in combination
with 10 mg of a vector expressing the oncogenic Ha-rasVal12, or with 30 mg of an expression vector for the dominant negative Ras mutant RasAsn17.
CAT activity was determined 48 h after transfection in control cells (2) and in cells treated with 10 mM forskolin (Fk) in the presence (black
bars) or absence (light bars) of 13 nM IGF-1. The data are the mean of the values obtained from two independent transfections with variation
less than 10–15%.
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reduced, by 30–50%, GHF-1/Pit-1 levels in GH3 cells. How-
ever, IGF-1 did not decrease the abundance of this transcrip-
tion factor in GH4C1 cells.
The influence of IGF-1 on GHF-1/Pit-1 mRNA levels also
was determined in both cell types. Figure 10 (panel B) shows
that two major classes of GHF-1/Pit-1 transcripts were
found: a more prominent 3.1-kb band and a less abundant
band of 1.2-kb. A fainter transcript of approximately 4 kb also
was often detected. In agreement with the GHF-1/Pit-1 pro-
tein concentrations, the level of GHF-1/Pit-1 transcripts was
reduced by IGF-1 in GH3 but not in GH4C1 cells. As in the
case of the PRL and GH promoters, the activity of the GHF-
1/Pit-1 promoter in transient transfection assays was not
reduced by IGF-1 in GH3 cells (data not shown).
Figure 11 shows the levels of GHF-1/Pit-1 transcripts in
GH4C1 and GH3 cells treated with T3, RA, and Fk in the
presence and absence of IGF-1. As illustrated in panel A, in
GH3 cells, the inhibition of GHF-1/Pit-1 transcripts by IGF-1
was less marked than that caused by T3, and the combination
of both did not produce further decreases. In addition, IGF-
1-mediated reduction of GHF-1/Pit-1 mRNA levels was sig-
nificantly attenuated in the presence of RA or Fk. Figure 11B
shows that IGF-1 alters neither basal levels of GHF-1/Pit-1
mRNA nor RA-dependent stimulation or T3-dependent in-
hibition in GH4C1 cells.
The lack of response of the PRL promoter to IGF-1 in GH3
cells may reflect the presence of limiting amounts of GHF-
1/Pit-1 in these cells. To directly test this hypothesis, the
effect of IGF-1 on the 23000Prl-CAT construct also was ex-
amined in GH3 and GH4C1 cells transfected with an ex-
pression vector encoding GHF-1/Pit-1. As shown in Fig. 12,
expression of GHF-1/Pit-1 had little, if any, effect on PRL
promoter activity in GH4C1 cells. However, basal promoter
activity increased in GH3 cells transfected with GHF-1/Pit-1;
and under these conditions, IGF-1 did not decrease the ac-
tivity of the PRL promoter but, instead, increased promoter
activity by approximately 2-fold.
Discussion
This work presents evidence of alternate inhibition or
stimulation of the PRL gene by IGF-1 in two different rat
pituitary cell lines. Whereas in GH4C1 cells, expression of
this gene is strongly induced by IGF-1, in GH3 cells, the
growth factor reduces PRL transcripts and represses the re-
sponse to different PRL inducers, such as T3, RA, or Fk
(28–31). The GH gene, another pituitary-specific gene, also is
differentially regulated by IGF-1. The expression of GH is not
significantly affected by IGF-1 in GH4C1 cells but is reduced
in GH3 cells. We have previously shown that RA induces GH
gene transcription in GH1 and GH4C1 cells, and we have
mapped the RA response element to the same sequences that
mediate regulation by T3 (26, 27). Our present results show
that RA and T3 also induce GH gene expression in GH3 cells
and that this response is significantly attenuated by IGF-1.
The reduction of GH and PRL mRNA levels, caused by IGF-1
in GH3 cells, could reflect a decrease of transcription or could
be secondary to a posttranscriptional mechanism, leading to
mRNA destabilization. The latter mechanism was elimi-
nated, because the apparent half-life of GH and PRL mRNAs
was not reduced in IGF-1-treated GH3 cells.
The expression of the GH and PRL genes is dependent on
the binding of GHF-1/Pit-1 to their promoters. We have
found that IGF-1 decreases the amount of GHF-1/Pit-1 in
FIG. 9. IGF-1 activates MAP-K activity in GH3 and GH4C1 cells.
GH4C1 and GH3 cells were treated with 13 nM IGF-1 for the times
indicated or with 100 nM TPA for 10 min. Cell extracts were incubated
with an anti-ERK-2 antibody, and kinase activity in the immunopre-
cipitates was determined with g-32P-ATP and MBP as the substrate.
32P incorporation into MBP was quantitated by densitometry after
separation by electrophoresis in polyacrylamide gels.
FIG. 10. IGF-1 decreases GHF-1/Pit-1 expression in GH3 cells. Panel
A, The levels of GHF-1/Pit-1 protein were determined by immuno-
precipitation with an anti-GHF-1 antibody in untreated (2) GH4C1
and GH3 cells, and in cells treated with 13 nM IGF-1 for 48 h; panel
B, GHF-1/Pit-1 mRNA levels were determined by Northern blot in
GH4C1 and GH3 cells treated as in panel A. The sizes of the GHF-
1/Pit-1 transcripts found are indicated with arrows.
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GH3 cells and that this decrease is secondary to a reduction
in GHF-1/Pit-1 mRNA levels. This observation is in agree-
ment with a recent report (32) showing that IGF-1 inhibited
basal GHF-1/Pit-1 mRNA concentration and blunted the
response to GH-RH in primary cultures of rat anterior pi-
tuitary cells. However, GHF-1/Pit-1 levels were not reduced
by IGF-1 in GH4C1 cells. Furthermore, we have previously
described that whereas T3 decreases (33), RA increases (34)
GHF-1/Pit-1 mRNA levels, and these responses are not mod-
ified by IGF-1 in GH4C1 cells.
The reduction in the concentration of the transcription
factor that is required for the expression of both the GH and
PRL genes is certainly in agreement with the decreased levels
of their transcripts observed in IGF-1-treated GH3 cells. Un-
expectedly, the activity of the PRL and GH promoters, which
contain the binding sites for GHF-1/Pit-1, was not inhibited
by IGF-1 in GH3 cells in transient transfection assays. Al-
though we do not dismiss the possibility that the sequences
responsible for the inhibitory effect of IGF-1 on pituitary gene
expression in GH3 cells could be outside the promoter frag-
ments examined, it seems likely that the results obtained in
the transient transfection assays do not exactly reflect the
behavior of the endogenous gene. Discrepancies between the
regulation of the endogenous PRL gene and the transiently
transfected promoter have been previously reported to occur
for the regulation of this gene by insulin. It has been found
that insulin (as observed by us with IGF-1 in these cells)
stimulates expression of the endogenous gene but, under
identical conditions, does not stimulate PRL-CAT plasmids
(35, 36). The authors attribute the lack of response of the
transfected gene to the existence of low levels of insulin
receptors in these cells, because cotransfection with an in-
sulin receptor expression plasmid was required to observe
insulin stimulation of the PRL promoter. Furthermore, it has
been previously shown (37) that GH3 cells are relatively
FIG. 11. Regulation of GHF-1/Pit-1 mRNA levels by IGF-1, T3, RA, and forskolin in GH4C1 and GH3 cells. RNA obtained from GH3 cells (panel
A) and GH4C1 cells (panel B) was used for Northern blot analysis with the GHF-1/Pit-1 cDNA probe. The RNA was obtained from control
untreated cells and from cells incubated with 5 nM T3, 1 mM RA, or 10 mM forskolin (Fk) in the presence or absence of 13 nM IGF-1, as indicated.
FIG. 12. Effect of expression of GHF-1 on the PRL promoter response
to IGF-1. GH4C1 and GH3 cells were transfected with 10 mg of
3000Prl-CAT alone (2) or in combination with 10 mg of a vector
expressing GHF-1. CAT activity was determined 48 h after transfec-
tion in control cells and in cells treated with 13 nM IGF-1. The data
represent the mean 6 SD of the values obtained from three indepen-
dent cultures.
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resistant, as compared with GC cells, to the action of IGF-1
because they contain a lower number of IGF-1 receptors.
Therefore, it was likely that the concentration of the IGF-1
receptors may be insufficient in GH3 cells to cause a reduc-
tion in the activity of the GH and PRL promoters in transient
transfection assays. However, this possibility can be dis-
missed, because the overexpression of IGF-1 receptors does
not confer a significant promoter response to IGF-1 in GH3
cells. In contrast, IGF-1 stimulation of the PRL promoter is
observed in GH3 cells transfected with an expression vector
encoding GHF-1/Pit-1. This result, which further suggests a
role of the endogenous GHF-1/Pit-1 concentration in the
differential response to IGF-1, is in agreement with the find-
ing that overexpression of the transcription factor also en-
hances activation of the PRL promoter by Ras in GH4C1 cells
(12).
In contrast to the findings in GH3 cells, the PRL promoter
is significantly activated by IGF-1 in GH4C1 cells, and this
response is further enhanced upon overexpression of the
IGF-1 receptor. Stimulation by the growth factor in GH4C1
cells requires activation of the Ras/MAP-K pathway, be-
cause it is blocked by a dominant negative Ras mutant. It was
then possible that some component of this pathway was
defective in GH3 cells. Our results show that the pathway
downstream of Ras is intact, because oncogenic Ras clearly
activates the PRL promoter in GH3 cells. It also was possible
that a component linking the IGF-1 receptor to Ras was
uncoupled in these cells. If this were the case, IGF-1 should
not activate this signaling pathway. However, the growth
factor transiently stimulated MAP-K activity in GH3 cells.
Both the intensity and the time-course of the activation were
similar in GH3 and GH4C1 cells. From these results, it can
be deduced that the defect occurs in other pathway(s), in
addition to the Ras/MAP-K cascade. Although IGF-1 is a
potent growth factor for other cell types, it exerts little mi-
togenic effects in pituitary cells (6). The rapid induction of
MAPK activity, after incubation with growth factors, is fol-
lowed by a slower and persistent late phase of activity that
correlates with mitogenic activity, and no second phase of
activation is observed in GC, GH4C1, or GH3 cells (Ref. 6,
and this study). Therefore, the influence of IGF-1 on pituitary
gene expression should not merely reflect changes in cell
growth and the cell cycle.
The existence of an additional signaling pathway that di-
verges after receptor activation and contributes to the stim-
ulation of the PRL promoter by IGF-1 is suggested by the
finding that, in GH4C1 cells, IGF-1 can further increase the
activity of the PRL promoter in the presence of oncogenic
Ras. It is interesting that EGF, also a ligand of a tyrosine
kinase receptor, activates the PRL promoter by a Ras-inde-
pendent mechanism in pituitary GH4 cells (38). The exact
mechanism by which this factor regulates the PRL gene is still
unknown, but it is well established that ligand-activation of
different receptor tyrosine kinases allows several proteins to
become associated with specific phosphotyrosines and to
initiate different signaling cascades. Our results are compat-
ible with a model in which IGF-1 uses both the Ras/MAP-K
and other pathway(s) to activate the IGF-1 gene. Stimulation
of such pathways would be required for the IGF-1 action.
GH3 cells would be deficient in the second pathway and,
therefore, in stimulation of the PRL promoter, whereas
GH4C1 cells would respond to IGF-1 by stimulating both
pathways and, consequently, the PRL gene. That the second
pathway is alone insufficient for this stimulation is shown by
the finding that the dominant negative Ras mutant abolishes
the IGF-1 response in GH4C1 cells. The finding that onco-
genic Ras, but not IGF-1, is able to activate the PRL promoter
in GH3 cells suggests that a strong and sustained stimulation
of Ras, that is not obtained when the endogenous Ras is
transiently activated by IGF-1, is required to achieve PRL
promoter activation.
Although different pituitary cell lines are normally indis-
tinctly used in studies of hormonal regulation of gene ex-
pression, there are previous reports of differential regulation
in different pituitary cell lines. This is especially true for the
PRL gene. For instance, T3 decreases PRL gene expression in
GH1 cells, whereas it increases PRL transcripts in GH3 and
GH4C1 cells (Refs. 21 and 30, and this study). Furthermore,
insulin has been shown to stimulate the PRL gene in GH4C1
cells (31, 35, 39) without affecting PRL expression in primary
pituitary cultures (8). Pituitary gene response to IGF-1 in
primary cultures of rat anterior pituitary cells is rather sim-
ilar to that found by us in GH3 cells and strikingly different
to that observed in GH4C1 cells. IGF-1 has an inhibitory
effect on GH and GHF-1/Pit-1 gene expression in GH3 and
normal pituitary cells, but it has a specific stimulatory effect
on PRL transcription without affecting GH or GHF-1/Pit-1
expression in GH4C1 cells. The different behavior of the two
cell lines could be related to the fact that, although both are
tumor cells, the GH3 cells are not variant cell lines and thus
are presumably one step closer than GH4C1 cells to their
normal counterparts. Regulation of pituitary gene expression
provides a powerful tool for future studies on the delineation
of the molecular mechanisms by which the same hormone or
growth factor can repress or stimulate the same gene in
closely related cell types.
Finally, the action of IGF-1 in the pituitary axis must be
complex and should take into account other factors such as
IGF-2 or the IGF-binding proteins (IGFBPs). Although our
experiments have been performed in the absence of serum,
how each of the different binding proteins function to aug-
ment or inhibit the effect of IGF-1 in pituitary gene expres-
sion, or how IGF-1 works in conjunction with IGF-2 or other
factors, has not yet been delineated and will require future
studies.
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